The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibGuidelines for the management of myeloproliferative neoplasmsImpact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FNew Therapeutic Approaches in Polycythemia VeraAdvances in the management of myelofibrosisThe evolving treatment paradigm in myelofibrosisManaging Patients With Myelofibrosis in the Era of Janus Kinase InhibitorsThe Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential ThrombocythemiaMomelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Practical management of myelofibrosis with ruxolitinib.Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Polycythemia Vera Management and Challenges in the Community Health Setting.Current and future treatment options for polycythemia vera.Emerging treatments for essential thrombocythemiaMyeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisDiagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableReal-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNsPhase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosisNovel and emerging therapies for the treatment of polycythemia veraSymptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.What's different about atypical CML and chronic neutrophilic leukemia?Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
P2860
Q26750696-6DB6F287-A502-4F6B-B333-4074DAEA86D4Q26778326-384DD8E4-DD78-4348-8D4C-BF3C3E709DE6Q26779947-682087DF-5C8A-4116-95B3-6ADCFDFE88FCQ26795666-FE9D800D-B98D-4E0E-AFCC-5911178797ABQ26795677-B8ABF1AA-3C7F-4AD3-B618-B219D7A8B2A6Q27008072-12B4F542-82BA-4C7D-BCB8-24C449BF323BQ27021968-B5BECE8B-7DDF-4912-8F8F-995198CBB12CQ28073296-9E355AA6-CC7D-4857-83E8-99914A69A160Q28074777-C2FD23ED-BDAB-449D-849B-292FDA86B7CCQ30244032-3E68F59E-12DB-426F-86A4-F7A57DA221C8Q30992878-F1F54E3A-7A49-4620-8A87-E9AAC1F93E68Q33405985-809BCFEA-139F-4EA7-9AE6-F284FE0B46F9Q33406238-042D5518-BA4F-47B4-BE08-266C0F05D1E6Q33411637-E5F2DCEF-84EA-40A9-985E-0ECFA6B553EDQ33413428-294F6554-65D0-40E2-AE73-4C16A33C3815Q33428259-49509EE0-B4DB-4CE9-AFAB-AD9581795CFEQ33434734-3CC8207A-9F79-40EE-BA00-E4A8FBC7D463Q33435178-4C867BA4-B897-43A1-89B6-5690A730E1E3Q33438420-52C74455-9B28-4CC1-AAA6-E491CDDE654EQ33803036-DA154B02-4B84-43DB-823A-46DCBF14D33EQ35572748-FAA51B70-F1F6-4A8E-ABD3-FCC430585EFBQ35683853-95BA3C30-3243-4192-AD74-D2D9E9CCC8E8Q35938283-0A1EF2E7-BC51-4940-BFB4-B7A16C84C4F2Q36003480-A31EC3AD-7F3F-48C4-87DA-C2B2D4F0E62AQ36022526-E01F4577-0481-4A09-96BF-F54F01DF27A0Q36266377-4BE0A40B-0310-4824-BBC7-4AE7ECAE81DDQ36305314-9CB0CF6A-36D3-4B55-B126-E446216273B1Q36708989-880300AA-9111-4CC8-B0EC-F8D69DEDE978Q36907860-3B7218F0-55FE-4233-A17A-D80A05899EA2Q36915139-1D4EDC65-C387-4B92-9AE9-8E41CCA6283FQ37034988-447BD29D-C545-419C-B453-D71EE6C65A14Q37069633-DEAD288A-38CC-4C34-9307-D6E4930AE32DQ37481181-BB551C59-F464-43FF-AE0C-3D5A83BB0742Q37555790-C500DC74-BA15-4485-BE17-1CFEA8C944E8Q37606895-0C5D5D7A-F359-44EC-822A-8503FDB2E7D8Q37631854-72DC02B5-642C-4FA3-933D-8A786B599E43Q37682689-37A9E779-BFE8-4110-9091-9F4D34F48407Q37998574-94170725-653D-4B58-9E3B-BE793FAD5B49Q38014534-1F30B9FD-4C17-48EE-A972-000BB9D84870Q38044736-A0E3D782-72A5-42B1-8C02-F4DBAE9C21E8
P2860
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The Myeloproliferative Neoplas ...... ability trial in 402 patients.
@en
The Myeloproliferative Neoplasm Symptom Assessment Form
@nl
type
label
The Myeloproliferative Neoplas ...... ability trial in 402 patients.
@en
The Myeloproliferative Neoplasm Symptom Assessment Form
@nl
prefLabel
The Myeloproliferative Neoplas ...... ability trial in 402 patients.
@en
The Myeloproliferative Neoplasm Symptom Assessment Form
@nl
P2093
P1433
P1476
The Myeloproliferative Neoplas ...... ability trial in 402 patients.
@en
P2093
Alessandro M Vannucchi
Alessandro Rambaldi
Amylou C Dueck
Bjorn Andreasson
Claire N Harrison
Deepti Radia
Giovanni Barosi
Gunnar Birgegard
Jan Samuelsson
Maria L Ferarri
P304
P356
10.1182/BLOOD-2011-01-328955
P407
P577
2011-05-02T00:00:00Z